Philip D. Home

Philip D. Home

Newcastle University Framlington Place
Newcastle Upon Tyne, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 132 publications

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long-Acting Insulin Analogues for Diabetes Mellitus.

The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long-Acting Insulin Analogues for Diabetes Mellitus.

Journal: Diabetes, obesity & metabolism

Published: January 31, 2026

Spatial dynamics of biodiversity and cycling behaviour: A geographical analysis using crowdsourced data from Strava Metro.

Spatial dynamics of biodiversity and cycling behaviour: A geographical analysis using crowdsourced data from Strava Metro.

Journal: Health & place

Published: August 13, 2025

An overview of insulin therapy for the non-specialist.

An overview of insulin therapy for the non-specialist.

Journal: Diabetes, obesity & metabolism

Published: January 02, 2025

Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies.

Efficacy and safety of iGlarLixi versus IDegAsp in people with type 2 diabetes inadequately controlled with basal insulin: A systematic literature review and network meta-analysis of non-Asian studies.

Journal: Diabetes, obesity & metabolism

Published: December 17, 2024

The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes.

The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes.

Journal: Diabetes care

Published: December 10, 2024

Insulin biobetters and biosimilars in clinical practice.

Insulin biobetters and biosimilars in clinical practice.

Journal: The journal of the Royal College of Physicians of Edinburgh

Published: May 18, 2023

Making sense of weekly insulins.

Making sense of weekly insulins.

Journal: The lancet. Diabetes & endocrinology

Published: December 22, 2022

Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.

Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics.

Journal: Diabetes, obesity & metabolism

Published: August 30, 2022

Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials.

Understanding Biosimilar Insulins - Development, Manufacturing, and Clinical Trials.

Journal: Journal of diabetes science and technology

Published: July 12, 2022

The path for medical associations to sponsor trustworthy guidelines: is it feasible?

The path for medical associations to sponsor trustworthy guidelines: is it feasible?

Journal: Journal of the Royal Society of Medicine

Published: April 29, 2022

Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.

Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial.

Journal: Diabetes, obesity & metabolism

Published: February 07, 2022

Lingering Effects of Hyperglycemia in Recently Diagnosed Diabetes During Long-term Follow-up of the DCCT/EDIC and UKPDS Cohorts: More Evidence That Early Control Matters.

Lingering Effects of Hyperglycemia in Recently Diagnosed Diabetes During Long-term Follow-up of the DCCT/EDIC and UKPDS Cohorts: More Evidence That Early Control Matters.

Journal: Diabetes care

Published: September 22, 2021

Showing 1-12 of 132

Last Updated: 09/26/2026